Galapagos receives transparency notifications
May 26 2015 - 4:06PM
Galapagos NV (Euronext & NASDAQ: GLPG) received transparency
notifications from the Capital Group Companies, Inc., Fidelity
Management and Research LLC, and Federated Equity Management
Company of Pennsylvania.
Pursuant to Belgian transparency legislation1,
Galapagos received a transparency notification on 21 May 2015 from
the Capital Group Companies, Inc., who notified that since 19 May
2015, entities under its control held 1,795,935 shares,
representing 4.68% of the current 38,403,176 outstanding Galapagos
shares. This is compared to the 1,554,436 shares reported in
the transparency notice Galapagos received from the Capital Group
Companies, Inc., on 5 September 2012.
Galapagos also received a transparency
notification on 21 May 2015 from Fidelity Management and Research
LLC, who notified that on 19 May 2015, entities under its control
held 2,732,508 shares, representing 7.12% of outstanding
shares. This is the first transparency notice received from
Fidelity Management and Research LLC.
Galapagos also received a transparency
notification on 20 May 2015 from Federated Equity Management
Company of Pennsylvania, who notified that on 14 May 2015, it
controlled the voting rights attached to the 2,238,000 shares
(representing 5.83% of outstanding shares) held by funds managed by
it. This is the first transparency notice received from
Federated Equity Management Company of Pennsylvania.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a
clinical-stage biotechnology company specialized in the discovery
and development of small molecule medicines with novel modes of
action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 20 discovery
small-molecule and antibody programs in cystic fibrosis,
inflammation, and other indications. In the field of
inflammation, AbbVie and Galapagos signed a collaboration agreement
for the development and commercialization of filgotinib.
Filgotinib is an orally-available, selective inhibitor of JAK1 for
the treatment of rheumatoid arthritis and potentially other
inflammatory diseases, currently in Phase 2B studies in RA and in
Phase 2 in Crohn's disease. Galapagos reported good activity and a
favorable safety profile at 12 weeks in both the DARWIN 1 and 2
trials in RA. AbbVie and Galapagos also signed a
collaboration agreement in cystic fibrosis to develop and
commercialize molecules that address mutations in the CFTR
gene. Potentiator GLPG1837 is currently in a Phase 1 trial,
and corrector GLPG2222 is at the pre-clinical candidate
stage. GLPG1205, a first-in-class inhibitor of GPR84 and
fully-owned by Galapagos, is currently being tested in a Phase 2
proof-of-concept trial in ulcerative colitis patients.
GLPG1690, a fully proprietary, first-in-class inhibitor of
autotaxin, has shown favorable safety in a Phase 1 trial and is
expected to enter Phase 2 in idiopathic pulmonary fibrosis.
The Galapagos Group, including fee-for-service subsidiary
Fidelta, has approximately 400 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands,
France, and Croatia.
CONTACT
Galapagos NV Elizabeth Goodwin, Head of
Corporate Communications & IR Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, all of
which involve certain risks and uncertainties. These statements are
often, but are not always, made through the use of words or phrases
such as "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to,"
"continues," "we believe," "we intend," as well as similar
expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which
might cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial
conditions, performance or achievements expressed or implied by
such forward-looking statements. Among the factors that may
result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities, regulatory approval requirements and
estimating the commercial potential of our product
candidates. A further list and description of these risks,
uncertainties and other risks can be found in the company's
Securities and Exchange Commission filing and reports, including in
the company's prospectus filed with the SEC on May 14, 2015 and
future filings and reports by the company. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based, unless required by law or
regulation.
1 Belgian Act of 2 May 2007 on the disclosure of major
shareholdings in issuers whose shares are admitted to trading on a
regulated market
HUG#1923895
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024